Persistent Hiccups

Clinical Snapshot

A hiccup is an involuntary, spasmodic contraction of the diaphragm and inspiratory intercostal muscles, immediately followed by sudden closure of the glottis that produces the characteristic sound. Hiccups lasting under 48 hours are extremely common, self-limited, and rarely need active management. Persistent hiccups (48 hours to 1 month) and intractable hiccups (over 1 month) are a different clinical problem: they are driven by irritation somewhere along the hiccup reflex arc — the vagus and phrenic nerves, the brainstem "hiccup centre," or the efferent pathway to the diaphragm and glottis — and can be caused by an extraordinarily broad range of underlying conditions spanning the gastrointestinal tract, central nervous system, metabolic status, thorax and abdomen, and medication exposure.^[1] Left unaddressed, they can cause real functional harm — insomnia, inability to eat normally, exhaustion, and mood disturbance. Because management is most effective when directed at the underlying cause rather than at the hiccup reflex itself, identifying that cause — with a pharmacist-led medication review playing a central role — is the first and most important step, before any drug is chosen purely to suppress the hiccups.^[2]

Recognize the Condition

What a hiccup episode looks like

Each hiccup is a brief, involuntary inspiratory spasm of the diaphragm (often with the external intercostal muscles), terminated abruptly by glottic closure — the two events together produce the characteristic "hic" sound. Episodes can recur several times per minute and are not under voluntary control once established.

Classifying hiccups by duration determines the whole approach

Acute hiccups (under 48 hours)

By far the most common pattern. Usually self-limited and resolves with simple physical maneuvers or no treatment at all; not the focus of this chapter.

Persistent hiccups (48 hours to 1 month)

Hiccups continuing beyond the self-limited window. Warrants a targeted search for an underlying cause and, if none is found or none is immediately treatable, a therapeutic trial to stop the hiccups directly.^[1]

Intractable hiccups (over 1 month)

The most severe end of the spectrum, using the same diagnostic approach as persistent hiccups. The functional impact — sleep loss, weight loss, exhaustion — is typically more pronounced, and the threshold for pursuing further investigation and more aggressive or invasive treatment is lower.

Risk Factors

Gastrointestinal disease — gastroesophageal reflux, gastric distention or delayed emptying, esophagitis, subphrenic or intra-abdominal abscess, pancreatitis, bowel obstruction.
Central nervous system disease — brainstem stroke, tumour, multiple sclerosis plaque, hydrocephalus, or traumatic brain injury affecting the medullary "hiccup centre" or its connections.
Thoracic or mediastinal disease — pneumonia, pleuritis, pericarditis, myocardial infarction, mediastinal mass or lymphadenopathy.
Recent abdominal or thoracic surgery, including esophagectomy and other procedures that irritate the diaphragm or phrenic nerve directly.
Metabolic disturbance — uremia or renal failure, electrolyte disturbance (hyponatremia, hypocalcemia), hypoglycemia.
ENT causes — pharyngitis, laryngitis, goitre, or a foreign body or hair irritating the external auditory canal (a branch of the vagus nerve supplies the ear canal).
Malignancy — direct tumour invasion or compression of the vagus or phrenic nerve, the diaphragm, or the mediastinum.
Medication exposure — see Assessment and Diagnosis for the specific drug classes most often implicated; a full medication and alcohol history is part of the standard work-up for every patient.
Alcohol use.
Older age and male sex.
Occasionally no identifiable cause is found even after a thorough work-up; a psychogenic contributor is only considered after organic causes have been reasonably excluded.

Red Flags & Refer

Persistent or intractable hiccups are usually benign, but the underlying-cause search exists specifically to catch the exceptions below — escalate or refer for any of the following:

Hiccups accompanied by neurological symptoms — headache, visual change, limb weakness, ataxia, or altered mental status — suggesting a CNS structural cause that needs urgent imaging.
Hiccups accompanied by significant unintentional weight loss, dysphagia, odynophagia, early satiety, or gastrointestinal bleeding — red-flag features suggesting an underlying malignancy rather than a benign cause.
Hiccups severe or persistent enough to cause significant sleep deprivation or exhaustion, or to prevent adequate oral intake.
New-onset persistent hiccups accompanied by fever or chest pain — screen for an infectious or cardiopulmonary cause (pneumonia, pericarditis, myocardial infarction) rather than assuming a benign cause.
Persistent hiccups arising in the immediate postoperative period after thoracic or abdominal surgery — rule out a surgical complication (subphrenic abscess, anastomotic leak, mediastinitis) before treating symptomatically.
Hiccups that remain refractory despite adequate trials of standard non-pharmacologic measures and at least 2 pharmacologic agents from different classes — refer for specialist assessment and consideration of more invasive options.

Assessment & Diagnosis

History

Take a targeted history — including a complete medication list and alcohol use — looking specifically for a cause of vagus or phrenic nerve irritation, malignancy, or CNS or gastrointestinal disease.^[1] Ask about timing relative to any new medication, recent surgery, chemotherapy, or radiation; associated GI symptoms (heartburn, early satiety, dysphagia); and neurological symptoms.

Medication-induced hiccups — a pharmacist-specific differential. Drug-induced persistent hiccups are uncommon but genuinely under-recognized, because the causative drug is often started well before the hiccups begin and the connection is never made on history unless specifically sought.^[2]

Corticosteroids, particularly dexamethasone — the best-documented drug-induced cause; hiccups can begin within hours of a dose and have been specifically reported with high-dose IV dexamethasone given as chemotherapy premedication. Switching to an equivalent dose of a different corticosteroid (for example, methylprednisolone or prednisolone) has resolved hiccups in reported cases without compromising the original indication.^[3]
Benzodiazepines — can precipitate or worsen hiccups; this is a paradoxical effect distinct from their usual sedative or anxiolytic use, reported with midazolam and other agents in this class.^[4]
Opioids — an infrequently reported but real cause; case reports describe hiccups recurring with morphine, codeine, and hydromorphone that resolved after switching to fentanyl, suggesting the effect may not be a uniform class effect across all mu-opioid agonists.^[5]
Alcohol.
Other agents reported in case literature: certain chemotherapeutic agents, and other CNS-active or general-anesthetic drugs.

When a temporally-associated causative drug is identified, discontinuing, reducing, or rotating that agent is the first management step — before adding a new drug purely to suppress the hiccups it is causing.

Physical examination

General exam, a full neurological exam, and abdominal and chest exam, looking for signs pointing toward one of the causes above.

Investigations

If history and physical exam identify no abnormalities, it is reasonable to perform baseline laboratory tests (CBC, electrolytes, creatinine) and a chest x-ray.^[1] Further investigation — upper GI tract endoscopy, CT of the thorax and abdomen, abdominal ultrasound — is guided by findings from this initial approach rather than ordered routinely; do not pursue advanced imaging in a patient with an unremarkable history, exam, and initial screening tests. If gastroesophageal reflux disease is identified or strongly suspected as the underlying cause, treat it directly per standard GERD management (see the Gastroesophageal Reflux Disease chapter) rather than relying on an anti-hiccup drug alone — reflux-directed therapy is expected to resolve reflux-driven hiccups on its own. If all investigations are negative, or an identified cause cannot be corrected, a therapeutic trial to stop the hiccups directly is warranted.^[1]

Treatment Targets

Stop or meaningfully decrease the frequency and intensity of hiccups, sufficient to resolve the functional impairment that brought the patient to care — restored sleep, ability to eat normally, and relief of exhaustion or distress.
Identify and directly treat any underlying cause found, rather than relying on symptomatic suppression alone.
Prevent recurrence.
When chronic therapy is required, reach the lowest effective maintenance dose, ideally as a single daily dose.
Avoid unnecessary long-term sedative, anticholinergic, or extrapyramidal drug burden when a better-tolerated agent achieves the same control.

Choose Initial Treatment

Direct treatment rule

Step 1 — treat the underlying cause whenever one is found

If history, exam, or investigations identify a specific reversible cause — reflux disease, gastric distention, an offending medication, a metabolic abnormality — treat that cause directly first; this is expected to resolve the hiccups without a separate anti-hiccup drug.^[2]

Step 2 — trial non-pharmacologic maneuvers

Before starting drug therapy, a brief trial of simple non-pharmacologic maneuvers is reasonable given their minimal risk, even though they lack formal evidence in persistent or intractable hiccups specifically (see Non-Pharmacologic Treatment for the honest evidence picture).

Step 3 — start pharmacotherapy if the cause cannot be identified or corrected, or hiccups persist despite cause-directed treatment

1st line baclofen or gabapentin — increasingly preferred as initial pharmacotherapy because they carry a lower risk of sedative, anticholinergic, and extrapyramidal adverse effects than the dopamine-antagonist agents during longer-term use.^[2]^[6]

1st line, equally reasonable chlorpromazine — the only agent with a formal regulatory indication for intractable hiccups (US FDA), with the most established dosing of any agent in this chapter; a fully reasonable first choice, particularly when a parenteral option may be needed if oral therapy fails.^[7]^[8]

Alternative metoclopramide — randomized-trial evidence supports a modest benefit; a reasonable option particularly when delayed gastric emptying is a plausible contributor.^[9]

Do not use benzodiazepines to manage persistent hiccups — they have been reported to precipitate or worsen hiccups rather than relieve them.^[4]

Step 4 — assess response on a fixed timeline

Reassess after 2-3 days: if the drug is ineffective, stop it rather than continuing longer or escalating the dose indefinitely; if effective, begin tapering after 1-3 days to find the lowest dose that keeps hiccups controlled (see Monitoring and Follow-up).^[1]

Non-Pharmacologic Treatment

Physical maneuvers

Techniques such as posterior pharyngeal wall stimulation with a finger, forced expiration against a closed glottis for about 10 seconds while seated, breath-holding, and breathing into a paper bag are widely used for acute hiccups, but there is no formal evidence supporting them specifically for persistent or intractable hiccups.^[1] Given their minimal risk, a brief trial is reasonable while pursuing the underlying-cause work-up, but do not rely on them as definitive therapy once hiccups have already become persistent.

Gastric decompression

If gastric distention is identified as the cause, gastric aspiration (for example, by nasogastric tube) is worth trying and can be both diagnostic and therapeutic.^[1]

Acupuncture

Poor-quality studies have reported temporary or permanent relief of intractable hiccups with acupuncture, but no randomized, placebo-controlled trials have been published — treat this as a low-evidence adjunct a patient may choose to pursue, not a recommended first-line intervention.^[1]

Continuous cervical epidural block

Has shown a high success rate in case series when multiple sessions (usually 2-3) are used. Reserve for refractory cases under specialist (anesthesia or pain-service) direction after pharmacotherapy trials have failed — see Treatment Failure and Next Step.^[1]

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Baclofen Preferred	1st-line initial pharmacotherapy	Start 5 mg PO BID; increase gradually every 2-3 days to a maximum of 80 mg/day	Sedation, muscle weakness, dizziness, lowered seizure threshold	Preferred for better long-term tolerability than the dopamine antagonists. Reduce the dose substantially in renal impairment. Taper gradually if effective — do not stop abruptly.
Gabapentin Preferred	1st-line initial pharmacotherapy	300 mg PO TID; may increase to 900-1800 mg/day in divided doses	Sedation, dizziness, ataxia	Preferred for better long-term tolerability than the dopamine antagonists. Evidence is from case series rather than randomized trials. Renally cleared — adjust for renal impairment.
Chlorpromazine Preferred	1st line, only formally-indicated agent	25-50 mg PO TID-QID for 2-3 days; escalate to parenteral therapy if ineffective after 2-3 days	Anticholinergic effects, extrapyramidal effects, hypotension, sedation, seizure, weight gain, photosensitivity, QTc prolongation	The only agent with a formal US FDA-approved indication for intractable hiccups. Stop after 2-3 days if ineffective; taper gradually to the lowest effective dose if effective.
Metoclopramide Alternative	2nd-line agent, or when gastric emptying is a plausible contributor	10 mg PO/IM/IV TID-QID for 2-3 days	Diarrhea, abdominal cramps, hyperprolactinemia, sedation, extrapyramidal effects, headache	The only dopamine antagonist besides chlorpromazine's labeled dosing with randomized, placebo-controlled trial support (a small pilot study).
Haloperidol Alternative	Alternative dopamine antagonist	0.5-4 mg PO TID for 2-3 days	Sedation, extrapyramidal effects, QTc prolongation	Case-report-level evidence only. An IM formulation has also been used in case reports when oral therapy is not feasible.

Special Populations

Pregnancy

Persistent or intractable hiccups have not been specifically studied in pregnancy. Identify and treat any reversible underlying cause first, since this avoids drug exposure altogether whenever possible. If pharmacotherapy is needed, metoclopramide has the most established pregnancy safety experience among the agents in this chapter, given its extensive use for nausea and vomiting in pregnancy; reserve chlorpromazine, baclofen, and gabapentin for when metoclopramide is inadequate or not tolerated, and involve obstetric care in the decision.

Breastfeeding

Metoclopramide is compatible with breastfeeding. Baclofen and gabapentin are both present in breast milk in small amounts and are generally considered compatible with breastfeeding, with infant monitoring for sedation. Chlorpromazine can cause infant sedation — use the lowest effective dose and monitor the infant if used during breastfeeding.

Pediatrics

Persistent or intractable hiccups are rare in children, and the evidence base for pharmacotherapy is even more limited than in adults. Not established for routine pediatric use with any of the agents in this chapter — use only under specialist direction with individualized, weight-based dosing rather than adult fixed doses.

Renal impairment

Baclofen is renally excreted — reduce the dose substantially in renal impairment (for example, start 2.5 mg PO BID rather than the usual 5 mg BID starting dose); neurotoxicity has been reported in patients with renal failure given standard doses.^[10] Gabapentin is also renally cleared and needs dose adjustment for reduced renal function — see the Drug Database entry for the full adjustment schedule.

Hepatic impairment

Chlorpromazine is hepatically metabolized — use caution and consider a lower starting dose in significant hepatic impairment.

Older adults

The population most affected by persistent and intractable hiccups.^[1] Older adults are more susceptible to the sedative, anticholinergic, and extrapyramidal effects of chlorpromazine, haloperidol, and metoclopramide, and to the sedation and fall risk of baclofen and gabapentin — start at the low end of the dosing range, titrate slowly, and reassess for these effects at every dose change.

Monitoring & Follow-Up

With an effective drug, hiccups generally stop abruptly within a few hours of starting therapy; in some cases the frequency and severity decrease more gradually over days rather than stopping abruptly.^[1] Once hiccups have been controlled for 1-3 days, begin tapering the dose; if hiccups do not return, continue tapering to discontinuation. If hiccups return during or after tapering, return to the lowest dose that reliably suppresses them — maintenance therapy, ideally as a single daily dose, is required in some patients.^[2] When a drug is ineffective, there is no need to continue treatment beyond 3 days before switching approach. Monitor for the specific adverse effects of whichever agent was chosen — extrapyramidal symptoms and QTc prolongation with the dopamine antagonists, sedation and renal-related neurotoxicity with baclofen, sedation and ataxia with gabapentin — and reassess in parallel whether any identified underlying cause is actually resolving, not only whether the hiccups themselves have stopped.

Treatment Failure / Next Step

Reconfirm no underlying cause was missed on the initial history, exam, or investigations — specifically re-review the full medication list for a causative drug (a corticosteroid, benzodiazepine, opioid, or other agent) that has not yet been stopped, reduced, or rotated.
If a first-line agent was genuinely ineffective after an adequate 2-3 day trial at an appropriate dose, stop it and switch to a different pharmacologic class rather than continuing to escalate the same drug indefinitely.
If GERD or another identified cause was targeted directly but hiccups have not resolved, reassess whether that cause has actually been adequately controlled before assuming the anti-hiccup drug itself has failed.
Pursue further investigation (upper GI tract endoscopy, CT of the thorax and abdomen, abdominal ultrasound) if not already done and an occult cause remains plausible.
For hiccups that remain refractory despite adequate sequential trials of at least 2 pharmacologic agents from different classes and no correctable cause found, refer for continuous cervical epidural block (typically 2-3 sessions under specialist direction).^[1]
Phrenic nerve block is reserved for cases where all other treatment modalities — pharmacologic and the interventions above — have genuinely failed; refer to an anesthesia or pain-management specialist rather than attempting this as an earlier-line option.^[11]

Common Errors to Avoid

Starting an anti-hiccup drug before completing a targeted history (including a full medication and alcohol review) and physical exam — most persistent hiccups have an identifiable, and sometimes directly treatable, cause.
Missing a medication-induced cause because the causative drug (a corticosteroid, benzodiazepine, or opioid) was started well before the hiccups began and the connection was never explicitly checked.
Using benzodiazepines to try to calm or sedate a patient with persistent hiccups — they can precipitate or worsen hiccups rather than relieve them.
Continuing an ineffective drug trial beyond 2-3 days instead of stopping and switching to a different class.
Stopping an effective agent abruptly instead of tapering — particularly relevant for baclofen, which should be tapered gradually once hiccups are controlled.
Failing to reduce the baclofen dose in renal impairment — a recognized cause of neurotoxicity at standard doses.
Ordering extensive imaging (CT thorax-abdomen, endoscopy) reflexively in a patient with an unremarkable history, exam, and initial screening labs/chest x-ray, instead of letting findings from that initial work-up guide further testing.
Treating an identified reversible cause, such as reflux disease, with an anti-hiccup drug alone instead of treating the underlying cause directly.

Clinical Decision Algorithm

Initial assessment and cause-directed treatment

Hiccups persisting beyond 48 hours (persistent) or beyond 1 month (intractable)

Screen for red flags: neurological symptoms, weight loss or GI red-flag symptoms, severe sleep or eating disruption, new fever or chest pain, postoperative onset

Red flags present

Urgent work-up, imaging, and referral as indicated by the specific red flag — do not manage as routine hiccups

No red flags

Targeted history (full medication and alcohol review) and physical exam for vagus/phrenic nerve irritation, malignancy, CNS, or GI disease

Specific reversible cause identified (e.g., reflux disease, an offending medication, a metabolic abnormality)

Treat the underlying cause directly — expected to resolve reflux- or medication-driven hiccups without a separate anti-hiccup drug

No abnormality on history or exam

CBC, electrolytes, creatinine, and chest x-ray; pursue endoscopy, CT thorax-abdomen, or ultrasound only if these are abnormal or suspicion remains^[1]

Pharmacotherapy selection and response

Hiccups persist despite cause-directed treatment, or no correctable cause is found — proceeding to a therapeutic trial

Brief trial of non-pharmacologic maneuvers (minimal risk; no formal evidence specifically in persistent/intractable hiccups)

Start baclofen or gabapentin (preferred for long-term tolerability) or chlorpromazine (the only formally-indicated agent) — see Pharmacologic Treatment Options for dosing

Effective within 2-3 days

Taper starting 1-3 days after response; find the lowest effective dose, often once daily; stop entirely if hiccups do not return

Ineffective after an adequate 2-3 day trial

Stop the drug; switch to a different pharmacologic class rather than escalating the same drug

Refractory despite 2 or more classes trialed and no missed cause: refer for continuous cervical epidural block

All modalities failed: phrenic nerve block as a last resort^[11]

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Dopamine Antagonists

The longest-studied class for persistent/intractable hiccups; chlorpromazine and haloperidol have case-report/case-series-level evidence, while metoclopramide has randomized, placebo-controlled trial support.

Drug	Dosage	Adverse effects	Comments
Chlorpromazine	Adults: 25-50 mg PO TID-QID for 2-3 days; if ineffective after 2-3 days, escalate to parenteral therapy Children: Not established for routine pediatric hiccup use — specialist-directed only.	Anticholinergic effects, extrapyramidal effects, hypotension, sedation, seizure (lowers seizure threshold), weight gain, photosensitivity, QTc prolongation	The only agent with a formal US FDA-approved indication for intractable hiccups; dosing follows that product labeling. If deemed ineffective, stop after 2-3 days. If deemed effective, taper gradually (e.g., every 1-3 days) to the lowest effective dose, given once daily if maintenance therapy is needed.^[7]^[8]
Haloperidol	Oral: 0.5-4 mg PO TID for 2-3 days Parenteral (case-report evidence): 2-5 mg IM, when oral therapy is not feasible Children: Not established for routine pediatric hiccup use — specialist-directed only.	Sedation, extrapyramidal effects, QTc prolongation	Case-report-level evidence only. Use the same stop/taper approach as chlorpromazine.^[8]
Metoclopramide	Adults: 10 mg PO/IM/IV TID-QID for 2-3 days Children: Not established for routine pediatric hiccup use — specialist-directed only.	Diarrhea, abdominal cramps, hyperprolactinemia, sedation, extrapyramidal effects, headache	The only dopamine antagonist besides chlorpromazine's labeled dosing with randomized, placebo-controlled trial support, in a small multicentre pilot study; may act via dopamine antagonism or by enhancing gastric emptying, making it a reasonable choice when delayed gastric emptying is a plausible contributor.^[9]

GABA-B Agonist

One of only two agents (with metoclopramide) studied in randomized, placebo-controlled trials for intractable hiccups, and — together with gabapentin — increasingly favoured as an initial choice given better long-term tolerability than the dopamine antagonists.

Drug	Dosage	Adverse effects	Comments
Baclofen	Adults: Start 5 mg PO BID; increase gradually every 2-3 days to a maximum of 80 mg/day Renal impairment: Reduce substantially — e.g., start 2.5 mg PO BID — and increase more cautiously; neurotoxicity has been reported at standard doses in renal failure Children: Not established for routine pediatric hiccup use — specialist-directed only.	Sedation, muscle weakness, nausea, dizziness, lowered seizure threshold	Renally excreted — see the renal-impairment dose line, and Special Populations. If deemed effective, do not stop abruptly; taper gradually (e.g., every 1-3 days) to find the lowest effective maintenance dose. Maintenance therapy is required in some cases.^[12]^[10]

Anticonvulsant

Observational (case-series) evidence supports gabapentin specifically; favoured alongside baclofen as an initial choice for the same tolerability reasons.

Drug	Dosage	Adverse effects	Comments
Gabapentin	Adults: 300 mg PO TID; may increase to 900-1800 mg/day in divided doses Renal impairment: Reduce the dose for reduced renal function — see the Drug Database entry for the full adjustment schedule Children: Not established for routine pediatric hiccup use — specialist-directed only.	Sedation, dizziness, ataxia, peripheral edema	Evidence is from case series rather than randomized trials. Use the same stop/taper approach as the other agents in this table.^[2]^[6]

Other Agents — Case-Report-Level Evidence Only

Reserved for when the preferred agents above have failed or are contraindicated. Hiccup-specific dosing has not been established in controlled trials for any of these agents — dose within the drug's standard indication-specific range under specialist guidance rather than assuming the doses used for hiccups above apply.

Drug	Dosage	Adverse effects	Comments
Amitriptyline	Adults: Not established for hiccups — dosed within the standard neuropathic-pain/depression range under specialist guidance	Anticholinergic effects, sedation, QTc prolongation, orthostatic hypotension	Case-report evidence only.^[2]^[8]
Carbamazepine	Adults: Not established for hiccups — dosed within the standard anticonvulsant range under specialist guidance, with therapeutic drug monitoring	Sedation, dizziness, hyponatremia, rare severe cutaneous or hematologic reactions	Case-report evidence only; requires baseline and follow-up monitoring bloodwork per the Drug Database entry.
Valproic acid	Adults: Not established for hiccups — dosed within the standard anticonvulsant range under specialist guidance	Sedation, GI upset, hepatotoxicity, thrombocytopenia	Case-report evidence only; contraindicated in pregnancy.
Amantadine	Adults: Not established for hiccups — dosed within the standard antiviral/antiparkinsonian range under specialist guidance	CNS stimulation, insomnia, livedo reticularis, hallucinations	Case-report evidence only; requires renal dose adjustment.
Nifedipine	Adults: Not established — formulation-specific; see comments	Hypotension, headache, flushing, reflex tachycardia	Case-report evidence only, using an immediate-release formulation distinct from the once-daily extended-release antianginal/antihypertensive product monographed in the Pharmasist Drug Database — confirm formulation carefully before use and do not substitute the extended-release product without specialist input.

References

Intractable hiccups — Current Neurology and Neuroscience Reports (Rouse S, Wodziak M). Curr Neurol Neurosci Rep 2018;18(8):51
Systematic review: the pathogenesis and pharmacological treatment of hiccups — Alimentary Pharmacology & Therapeutics (Steger M, Schneemann M, Fox M). Aliment Pharmacol Ther 2015;42(9):1037-1050
Corticosteroid rotation to alleviate dexamethasone-induced hiccup: a case series at a single institution — Journal of Pain and Symptom Management (Kang JH, Hui D, Kim MJ, et al.). J Pain Symptom Manage 2012;43(3):625-630
Hiccups induced by midazolam during sedation in flexible bronchoscopy — Archivos de Bronconeumologia (Arroyo-Cozar M, Grau Delgado J, Gabaldon Conejos T). Arch Bronconeumol 2012;48(3):103
Persistent Opioid-Induced Hiccups: A Case Report — Clinical Case Reports (Alhaj SS, Abdulhameed NM, Zaichenko M, Abu Ali AK). Clin Case Rep 2025;13(8):e70669
Pharmacotherapy for Chronic and Intractable Hiccups in Palliative Care: A Mixed Methods Systematic and Umbrella Review — Journal of Pain and Symptom Management (Das A, Halpin S, Kondasinghe JS). J Pain Symptom Manage 2026;71(3):e336-e358
Chlorpromazine Hydrochloride Tablets — FDA-approved product labeling — DailyMed, U.S. National Library of Medicine. DailyMed, accessed 2026
Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review — Journal of Emergency Medicine (Polito NB, Fellows SB). J Emerg Med 2017;53(4):540-549
Metoclopramide for patients with intractable hiccups: a multicentre, randomised, controlled pilot study — Internal Medicine Journal (Wang T, Wang D). Intern Med J 2014;44(12a):1205-1209
Baclofen-induced neurotoxicity in chronic renal failure patients with intractable hiccups — Southern Medical Journal (Chou CL, Chen CA, Lin SH, Huang HH). South Med J 2006;99(11):1308-1309
Phrenic Nerve Block for Intractable Hiccups: A Case Series — Cureus (Kalava A, Parikh S, Nguyen P, Ko C, Mandalaneni KK). Cureus 2025;17(11):e96975
Treatment of intractable hiccup with baclofen: results of a double-blind randomized, controlled, cross-over study — American Journal of Gastroenterology (Ramirez FC, Graham DY). Am J Gastroenterol 1992;87(12):1789-1791

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.